3 Things You Need to Know About Calciphylaxis: Earlier Intervention, Current Treatments, and Emerging Therapies

3 Things You Need to Know About Calciphylaxis: Earlier Intervention, Current Treatments, and Emerging Therapies

ReachMD Healthcare Image

How can you reach an early diagnosis of calciphylaxis in patients with CKD? Can emerging therapies complement your treatments plans? Find out now!

Available credits: 0.25

Time to complete: 15 minutes


Valid until:

Take Post-Test

If you’ve already completed the activity.

  • Overview

    High-quality evidence for the management of calciphylaxis is lacking due to the rare nature of the disease and its poorly understood pathogenesis. Our experts, Drs. Smeeta Sinha and Sagar Nigwekar, discuss the complexity of the condition, its diagnosis, treatment goals, and emerging therapies. Tune in to be sure you’re using all the tools at your disposal to improve your patients’ quality of life.

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Smeeta Sinha, PhD
    Professor of Nephrology
    Salford Royal Hospital
    Northern Care Alliance NHS FT
    Salford, United Kingdom

    Research: AstraZeneca, Johnson & Johnson, Vifor Pharma
    Consulting Fees: AstraZeneca, Bayer, Boehringer-Ingelheim, CSL Vifor, GSK, Inozyme Pharma Inc, Novartis, Sanifit, Sanofi Genzyme

    Sagar Nigwekar, MD
    Co-Director, Kidney Research Center
    Massachusetts General Hospital
    Harvard Medical School
    Boston, MA

    Research: Inozyme Pharma, Laboratoris Sanifit
    Receives Royalties: UpToDate
    Consulting Fees: Epizon Pharma, Fresenius Renal Therapies Group, Inozyme Pharma, Laboratoris Sanifit

    Reviewers/Content Planners/Authors:

    • Megan Clem has nothing to disclose.
    • Cindy Davidson has nothing to disclose.
    • Ann Early has nothing to disclose.
    • Hany Ibrahim, MD, has nothing to disclose.
    • Kate Nagele has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Identify signs and symptoms that should raise the clinical suspicion of calciphylaxis in patients with chronic kidney disease or end-stage kidney disease
    • Formulate an effective multidisciplinary, multicomponent treatment plan to manage patients with calciphylaxis
    • Identify how emerging therapies for calciphylaxis will complement current treatment approaches
  • Target Audience

    This activity is designed to meet the educational needs of nephrologists.

  • Accreditation and Credit Designation Statements

    In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.


    The American Medical Association has an agreement of mutual recognition of Continuing Medical Education (CME) credits with the European Union of Medical Specialists (UEMS), the accreditation body for European countries. Physicians interested in converting AMA PRA Category 1 Credits™ to UEMS-European Accreditation Council for Continuing Medical Education CME credits (ECMECs) should contact the UEMS at mutualrecognition@uems.eu.

    Global Learning Collaborative (GLC) designates this enduring activity for a maximum of .25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) designates this activity for .25 nursing contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider(s)/Educational Partner(s)

    Our ultimate goal is to improve the care being delivered to patients, and our high-quality, evidence-based CME initiatives reflect our dedication to the creation and execution of excellence and are the product of shared research, knowledge, and clinical practice skills across the healthcare continuum.

  • Commercial Support

    This activity is supported by an independent educational grant from CSL Vifor.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Medtelligence. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Medtelligence you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited
    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

Facebook Comments


We’re glad to see you’re enjoying Medtelligence…
but how about a more personalized experience?

Register for free